{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-065234","form_type":"8-K","ticker":"XLO","cik":"0001840233","company_name":"Xilio Therapeutics, Inc.","filed_at":"2026-02-24T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.482591+00:00","generated_at":"2026-05-16T00:52:53.649651+00:00","sec_items":["5.07"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Xilio Therapeutics stockholders approve reverse stock split at ratio from 1:2 to 1:30","bullets":["Stockholders approved reverse stock split at ratio between 1:2 and 1:30, board to set exact ratio and timing.","Proposal passed with 55,438,144 votes for, 1,521,271 against, 33,539 abstaining, no broker non-votes.","Adjournment proposal also approved with 55,461,067 for, 1,491,733 against, 40,154 abstaining.","Special meeting held on February 23, 2026; both proposals received overwhelming stockholder support."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-065234","json":"https://secwatch.observer/filing/0001193125-26-065234.json","markdown":"https://secwatch.observer/filing/0001193125-26-065234.md","text":"https://secwatch.observer/filing/0001193125-26-065234.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1840233/000119312526065234/0001193125-26-065234-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1840233/000119312526065234/xlo-20260223.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T00:52:53.649651+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}